Dual endothelin A and B receptor antagonist reduces office SBP in resistant hypertension
Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase
Presented at the AHA Scientific Sessions 2022 by: Prof. Markus Schlaich, MD- Perth, Australia
Introduction and methods
Resistant hypertension is defined by the inability to regulate blood pressure with 3 or more drug classes including inhibitors of the RAAS system (ACEi or ARB), calcium channel blockers and diuretics. The preferred fourth option for treatment of resistant hypertension is the MRA spironolactone that targets aldosterone.
However, failure of BP control with these currently available medications suggests that there are relevant pathophysiologic pathways that are not targeted, one of them possibly being the endothelin (ET) pathway. Indeed, ET has been implicated in the pathogenesis of hypertension by regulating water and sodium retention. ET exerts its BP-raising effect via vasoconstriction of VSMC and stimulation of aldosterone secretion.
In the PRECISION phase 3 trial, a dual ET A en B receptor antagonist (ERA) named aprocitentan was examined in patients with resistant hypertension.
Patients were screened on individual background anti-hypertensive medication if their BP was uncontrolled and then switched to standardized background therapy for 4 weeks. Eligible patients underwent a run-in period on placebo for 4 weeks followed by a first randomized phase. Patients were randomized to placebo (n=242), aprocitentan 12.5 mg (n=243) or aprocitentan 25 mg (n=245) for 4 weeks in the first part of the study. All patients then received aprocitentan 25 mg for 32 weeks (part 2) and were re-randomized to aprocitentan 25 mg or placebo for 12 weeks in part 3 (withdrawal phase). During the complete trial they stayed on standard background therapy. They were followed for an additional 30 days.
The primary endpoint was change from baseline tot week 4 in mean trough sitting office SBP.
- There was a clinically meaningful significant reduction of sitting office SBP in the aprocitentan groups (least square mean change was -15.3 (SE 0.9) mmHg for 12. 5 mg and -15.2 mmHg (0.9 mmHg) compared with the placebo group (-11.5 (0.9) mmHg) at 4 weeks (difference of least square mean was -3.8 mmHg, 97.5%CI:-6.8 to -0.8, P=0.0042 for 12.5 mg, and -3.7 mmHg, 95%CI: -6.7 to -0.8, P=0.0046 for 25 mg).
- In the phase 2 part of the trial, a reduction in office SBP was seen in those who hadn’t received aprocitentan before and a sustained reduction seen in those who continued aprocitentan.
- Office SBP rose in those who were randomized to placebo in the third part of the trial and BP lowering was maintained in patients who stayed on aprocitentan, with a significant finding between the two groups (P<0.0001) -the key secondary endpoint.
- Highly significant reduction in 24-h ambulatory SBP was observed with both doses aprocitentan compared with placebo (difference was -4.2 mmHg, 95%CI: -6.2 to -2.1 mmHg, P<0.001 for 12.5 mg and -5.9 mmHg, 95%CI: -7.9 to -3.8 mmHg, P<0.0002 for 25 mg) in part 1 of the trial, particularly during night-time. .
- 24-h Ambulatory SBP rose in those who were randomized to placebo (~8 mmHg at night-time) and BP lowering was maintained in those on aprocitentan in part 3.
- In subgroup analyses, elderly and those with micro- or macroalbuminuria, patients with impaired kidney function seem to benefit more from aprocitentan.
- ~30% Reduction in UACR was observed with aprocitentan in part 1, this was sustained in part 2 of the trial and when patients were re-randomized, UACR increased again in those on placebo while the decrease in UACR was maintained in those on aprocitentan in part 3.
- The most common adverse event was fluid retention/edema (9.1% of the aprocitentan 12.5 mg group, 18.4% of the aprocitentan 25 mg group and 2.1% of the placebo group in part 1 of the study; 18.2% of part 2 of the study; and 2.6% of patients in the aprocitentan group and 1.3% of the placebo group in part 3). HF hospitalization occurred in 2 patients on aprocitentan in part 1, in 6 patients in part 2, and 2 patients in part 3, and 1 patient in the placebo group.
Aprocitentan lowered office SBP and 24-h ambulatory SBP compared with placebo at 4 weeks in patients with resistant hypertension. BP lowering was maintained over 48 weeks. The most common adverse event was edema/fluid retention within the first 4 weeks of treatment.
- Our reporting is based on the information provided at the AHA Scientific Sessions 2022 -
Share this page with your colleagues and friends: